Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
暂无分享,去创建一个
H. Steinhart | A. Griffiths | A. Bitton | G. Greenberg | E. Seidman | C. Bernstein | R. Enns | J. Marshall | B. Feagan | R. Panaccione | G. Aumais | K. Croitoru | G. Wild | R. Fedorak | L. Sutherland | D. Sadowski | M. Fishman | C. Williams | M. Zachos | I. Rasul | E. Walli
[1] R S Wallis,et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[3] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[4] Kimberly M. Persley. Infliximab infusion reactions: desensitizing ourselves to the danger. , 2004, Inflammatory bowel diseases.
[5] S. Targan,et al. Infliximab in the treatment of medically refractory indeterminate colitis , 2003, Alimentary pharmacology & therapeutics.
[6] S. Anker,et al. Tumour necrosis factor-α and the failing heart , 2003, Basic Research in Cardiology.
[7] P. Lionetti,et al. Response to infliximab is related to disease duration in paediatric Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[8] M. Regueiro,et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.
[9] E. Chung,et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.
[10] J. Satsangi,et al. An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[11] G. Lichtenstein,et al. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent? , 2003, Gastroenterology.
[12] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[13] M. Braun,et al. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.
[14] J. Hugot,et al. A Prospective Study of the Efficacy and Tolerance of a Chimeric Antibody to Tumor Necrosis Factors (Remicade) in Severe Pediatric Crohn Disease , 2003, Journal of pediatric gastroenterology and nutrition.
[15] R. Caprilli,et al. Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.
[16] E. Cabré,et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab) , 2003, European journal of gastroenterology & hepatology.
[17] W. Sandborn. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. , 2003, Gastroenterology.
[18] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[19] R. Baldassano,et al. Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease , 2003, American Journal of Gastroenterology.
[20] M. Regueiro,et al. Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement , 2003, Inflammatory bowel diseases.
[21] E. Lundorf,et al. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[22] R. Kozarek,et al. Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions , 2003, American Journal of Gastroenterology.
[23] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[24] M. Kamm,et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging , 2003, Alimentary pharmacology & therapeutics.
[25] G. Marchal,et al. Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.
[26] R. Baldassano,et al. Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center , 2003, American Journal of Gastroenterology.
[27] W. Crandall,et al. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model , 2003, Alimentary pharmacology & therapeutics.
[28] J. Raftery,et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. , 2003, Health technology assessment.
[29] S. Hanauer,et al. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians , 2002, American Journal of Gastroenterology.
[30] A. Losco,et al. Drug side‐effects in IBD , 2002, Alimentary pharmacology & therapeutics.
[31] J. Mayberry,et al. Infliximab and Crohn's QOL , 2002, Alimentary pharmacology & therapeutics.
[32] J. Achkar,et al. Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.
[33] Antonio López-Vázquez,et al. High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease , 2002, American Journal of Gastroenterology.
[34] G. Porro,et al. Infliximab in treatment of Crohn's disease: the Milan experience. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[35] R. Modigliani,et al. An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease , 2002, Alimentary pharmacology & therapeutics.
[36] S. Kugathasan,et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction , 2002, American Journal of Gastroenterology.
[37] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[38] W. Tremaine,et al. Management of Internal Fistulas in Crohn's Disease , 2002, Inflammatory bowel diseases.
[39] C. Sample,et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[40] H. Steinhart,et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[41] P. Nos,et al. Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab , 2001, Inflammatory bowel diseases.
[42] S. Ghosh,et al. Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience , 2001, Alimentary pharmacology & therapeutics.
[43] J. Udall,et al. Use of Infliximab in Pediatric Patients with Inflammatory Bowel Disease , 2001, The Annals of pharmacotherapy.
[44] R. Cattell,et al. Infliximab treatment for Crohn's disease , 2001, Postgraduate medical journal.
[45] R. Panaccione. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[46] P. Rutgeerts,et al. Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.
[47] S. Kugathasan,et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.
[48] W. Sandborn,et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.
[49] W. Selby,et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. , 2001, Internal medicine journal.
[50] S. Hanauer,et al. Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.
[51] Samir A. Shah,et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease , 2000, American Journal of Gastroenterology.
[52] S. Kugathasan,et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease , 2000, American Journal of Gastroenterology.
[53] S. Nikolaus,et al. Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.
[54] J. Markowitz,et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.
[55] J. Hyams. Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents , 2000, The Journal of pediatrics.
[56] J. Marshall. A critical approach to clinical practice guidelines. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[57] M. Kamm,et al. Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.
[58] E. Vasiliauskas,et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.
[59] W. Sandborn,et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. , 1999, Gastroenterology.
[60] S. Targan,et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.